US Pharma MarketingADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect
As the American Diabetes Association 2026 Scientific Sessions kicked off in New Orleans over the weekend, Zealand Pharma and its partner Roche helped get the show rolling with a deep dive into thei As the American Diabetes Association 2026 Scientific Sessions kicked off in New Orleans over the weekend, Zealand Pharma and its recent commercial and development partner Roche helped get the show rolling with a deep dive into their amylin analog petrelintide. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology…
As the American Diabetes Association 2026 Scientific Sessions kicked off in New Orleans over the weekend, Zealand Pharma and its recent commercial and development partner Roche helped get the show rolling with a deep dive into their amylin analog petrelintide.
Source: FierceBiotech